Case Number 24: Generalized Seizure Disorder

Essentials of the Neurological Exam, Smith, Kline & French, Inc., 1968 Philadelphia.

Meadow S. R. : Anti-Convulsant Drugs and Congenital Abnormalities, Lancet 2: 1296, 1968.

Elshove J. : Cleft Palate in the Offspring of Female Mice Treated with Phenytoin, Lancet 2: 1074, 1969.

Watson J. D. Spellacy W. N. : Neonatal Effects of Maternal Treatment with the Anti-Convulsant Diphenylhydantoin, Obstet. Gynecol. 37: 881, 1971.

Kutt H. : Diphenylhydantoin Metabolism, Blood Levels and Toxicity, Arch. Neuro. 11: 642 (Dec.) 1964.

Holcomb R. : Intoxication with 5,5-Diphenylhydantoin (Dilantin). J. Peds. 80: 627 (Apr.) 1972.

Winthrop J. P. Kapur R. N. : Gingival Hyperplasia in Dilantin Therapy for Epileptics, Del. Med. J. pp 180 (Aug.) 1965.

Livingston S. : Hypertrichosis Occuring in Association with Dilantin Therapy, J. Peds. 47: 351, 1955.

Klipstein S. A. : Subnormal Serum Folate in Macrocytosis Associated with Anticonvulsant Drug Therapy, Blood 23: 68, 1964.

Reynolds E. H. : Anticonvulsant Therapy, Megaloblastic Hempoiesis, and Folic Acid Metabolism, Quart. J. Med. 35: 521, 1966.

Goldberg E. M. : Hyperglycemic, Nonketonic Coma Following Administration of Dilantin (Diphenylhydantoin), Diabetes 18: 101, 1969.

Fariss B. L. Lutcher C. L. : Diphenylhydantoin-Induced Hyperglycemia and Impaired Insulin Release: Effect of Dosage, Diabetes 20: 177, 1971.

Levin S. R. : Comparison of the Inhibitory Effects of Diphenylhydantoin and Diazoxide Upon Insulin Secretion from the Isolated Perfused Pancreas, Diabetes 21: 856, 1972.

Letteri J. M. : Diphenylhydantoin Metabolism in Uremia, New Engl. J. Med. 285: 648 (Sept. 16) 1971.

Hooper W. D. : Plasma Binding of Diphenylhydantoin, Clin. Pharmacol. Ther. 15: 276, 1974.

Arnold K. Gerber N. : The Rate of Decline of Diphenylhydantoin in Human Plasma, Clin. Pharmacol. Ther. 11: 121, 1970.

Buchanan R. A. : The Metabolism of Diphenylhydantoin (Dilantin) following Once-Daily Administration, Neurology 22: 126, 1972.

Wilder B. J. : Plasma Diphenylhydantoin Levels after Loading and Maintenance Doses, Clin. Pharmacol. Ther. 14: 797, 1973.

Easton J. D. : Diphenylhydantoin and Epilepsy Management, Ann. Intern. Med. 77: 421, 1972.

Wilensky A. J. Lowden J. A. : Inadequate Serum Levels after Intramuscular Administration of Diphenylhydantoin, Neurology 23: 318, 1973.

Serrano E. E. : Plasma Diphenylhydantoin Values after Oral and Intramuscular Administration of Diphenylhydantoin, Neurology 23: 311, 1973.

Letters to Editor: Drug Intelligence Clin. Pharm. 7: 287 (June) and 419 (Sept.) 1973.

Gallagher B. B. : Primidone, Diphenylhydantoin and Phenobarbital. Aspects of Acute and Chronic Toxicity, Neurology 23: 145, 1973.

Goodman L. D. Gilman A. : The Pharmacological Basis of Therapeutics 4th Edition. The Macmillan Co. New York, N.Y. 1970.

Gruber C. M. : Comparison of the Effectiveness of Phenobarbital, Primidone, Diphenylhydantoin, Ethotoin, Metharbital, and Methyl Phenylethylhydantoin in Motor Seizures, Clin. Pharmacol. Ther. 3: 23 1962.

Goodman L. S. : Anticonvulsant Properties of a 5-phenyl-5-ethylhexahydropyrimidine-4, 6-dione (Mysoline®), a new Antiepileptic, J. Pharmacol. Exp. Ther. 108: 428, 1953.

Woodbury D. M. : Anti Epileptic Drugs. Raven Press. New York, N. Y. 1972.

Wallis W. : Intravenous Diphenylhydantoin in Treatment of Acute Repetitive Seizures, Neurology 18: 513, 1968.

Anti Convulsant Drugs in Idiopathic Epilepsy, Med. Lett. Drugs Ther. 12: 53, 1970.